Patent intelligence · US
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
Patent details — US 12410137
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 9, 2025
- Expiration
- Sep 4, 2045
- Applicant
- APOGEE PHARMACEUTICALS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/443, A61K31/4436, A61K31/4439
Quick answer
US 12410137 (Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof) is held by APOGEE PHARMACEUTICALS, INC.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APOGEE PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/443, A61K31/4436, A61K31/4439, A61K31/5377, A61K45/06
More from APOGEE PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
granted -
US 12358979
Antibodies that bind interleukin 13 and methods of use
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8557800
Sphingosine kinase inhibitors
granted -
US 8063248
Sphingosine kinase inhibitors
granted -
US 7338961
Sphingosine kinase inhibitors
granted
Frequently asked questions
What is US patent 12410137?
US 12410137 (Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof) is held by APOGEE PHARMACEUTICALS, INC.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12410137?
APOGEE PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12410137 expire?
Our index shows an expiration date of Sep 4, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.